Nerandomilast is a newly FDA-approved oral medication for the treatment of idiopathic pulmonary fibrosis (IPF), developed by Boehringer Ingelheim and marketed as Jascayd. It is the first major new therapy for IPF granted approval in over a decade, addressing a significant unmet need in managing this severe and progressive lung disease. It is grouped under the following drug class(es): PDE4 inhibitors. The directory classifies it as a commercial API with a synthetic source/manufacturing origin. Other names for this substance include (1-(((5R)-2-(4-(5-chloropyrimidin-2-yl)piperidin-1-yl)-5-oxo-6, 7-dihydrothieno(3, 2-d)pyrimidin-4-yl)amino)cyclobutyl)methanol, (R)-2-(4-(5-Chloropyrimidin-2-yl)piperidin-1-yl)-4-((1-(hydroxymethyl)cyclobutyl)amino)-6, 7-dihydrothieno[3 and 2-d]pyrimidine 5-oxide. Its PubChem CID is 166177189.
Nerandomilast
| CAS No | 1423719-30-5 |
|---|---|
| Molecular Formula | C20H25ClN6O2S |
| Molecular Weight | 449.0 g/mol |
| Synonyms | [1-[[(5R)-2-[4-(5-chloropyrimidin-2-yl)piperidin-1-yl]-5-oxo-6,7-dihydrothieno[3,2-d]pyrimidin-4-yl]amino]cyclobutyl]methanol |
Zoho Contact Form
"*" indicates required fields
Frequently Asked Questions
Nerandomilast is a newly FDA-approved oral medication for the treatment of idiopathic pulmonary fibrosis (IPF), developed by Boehringer Ingelheim and marketed as Jascayd.
The listed CAS number is 1423719-30-5.
The listed molecular formula is C20H25ClN6O2S.
The listed molecular weight is 449.0 g/mol.
[1-[[(5R)-2-[4-(5-chloropyrimidin-2-yl)piperidin-1-yl]-5-oxo-6,7-dihydrothieno[3,2-d]pyrimidin-4-yl]amino]cyclobutyl]methanol.
The source lists (1-(((5R)-2-(4-(5-chloropyrimidin-2-yl)piperidin-1-yl)-5-oxo-6, 7-dihydrothieno(3, 2-d)pyrimidin-4-yl)amino)cyclobutyl)methanol, (R)-2-(4-(5-Chloropyrimidin-2-yl)piperidin-1-yl)-4-((1-(hydroxymethyl)cyclobutyl)amino)-6, 7-dihydrothieno[3 and 2-d]pyrimidine 5-oxide.